IMIrene Muñoz-Gallego

Irene Muñoz-Gallego

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irene Muñoz-Gallego has a total of 87 co-authors. Here are the top co-authors by number of shared publications:

  • Jaime Lora-Tamayo

    Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación “i + 12” del Hospital 12 de Octubre, 28041 Madrid, Spain

    4 shared publications
  • Esther Viedma

    Laboratory of Virology, Microbiology Department, Hospital Universitario, Madrid, Spain

    3 shared publications
  • Esther Viedma

    Department of Clinical Microbiology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

    3 shared publications
  • Jennifer Villa

    Department of Clinical Microbiology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

    3 shared publications
  • Consuelo Pascual

    Virology Laboratory Microbiology Department Hospital Universitario 12 de Octubre Madrid Spain

    2 shared publications
  • Fernando Chaves

    Department of Clinical Microbiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Biomédica ‘i+12’ Hospital 12 de Octubre , Madrid , Spain

    2 shared publications

Latest Publications

  • Open Access

    Impact of Susceptibility Testing Methodology on the Positioning of Cefiderocol and Aztreonam-Avibactam Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

    by Fernando del Nogal-Labrador, Beatriz González-Blanco, María Isabel Sanz, Raúl Recio, Patricia Brañas, Irene Muñoz-Gallego, Esther Viedma, Jennifer Villa

    Background/Objectives: The impact of antimicrobial susceptibility testing methodology on the categorization and positioning of cefiderocol and aztreonam-avibactam against metallo-β-lactamase (MBL)-producing Gram-negative bacilli remains unclear. This study aimed to evaluate the in vitro activity of cefiderocol and aztreonam-avibactam against clinical MBL-producing isolates and to assess the agreement between different cefiderocol susceptibility testing methods. Methods: A total of 299 non-duplicate clinical MBL-producing Gram-negative isolates were collected from clinical samples between 2022 and 2025. Antimicrobial susceptibility testing was performed using broth microdilution, disc diffusion, and gradient strip diffusion according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Carbapenemase genes were identified by immunochromatography and multiplex PCR. Categorical agreement and error rates between cefiderocol testing methods were analyzed. Results:Klebsiella pneumoniae was the predominant species, mainly producing NDM alone or in combination with OXA-48-like carbapenemases. Aztreonam-avibactam demonstrated complete activity against all Enterobacterales isolates (262/262, 100%) and high activity against Pseudomonas spp. (33/37, 89%). Cefiderocol susceptibility among Enterobacterales varied markedly depending on the testing method. Disc diffusion yielded 14% susceptibility (37/262), which increased to 52% (136/262) after ATU resolution, whereas broth microdilution showed 85% susceptibility (224/262). This resulted in low categorical agreement (42%) and a high rate of major errors (58%), with no very major errors detected. Cefiderocol activity did not differ substantially across carbapenemase types and was highest against VIM-producing Pseudomonas spp. Conclusions: Aztreonam-avibactam showed consistent in vitro activity against MBL-producing Enterobacterales, whereas cefiderocol activity was strongly influenced by the susceptibility testing methodology. Disc diffusion substantially underestimated cefiderocol susceptibility compared with broth microdilution. These findings highlight the critical impact of testing methodology on cefiderocol categorization and support the therapeutic role of last-line agents in the management of MBL-producing Gram-negative infections, with direct implications for clinical microbiology laboratories and antimicrobial stewardship programs.


  • Open Access

    A Study of Antibiotic Tolerance to Levofloxacin and Rifampin in Staphylococcus aureus Isolates Causing Prosthetic Joint Infections: Clinical Relevance and Treatment Challenges

    by María Ángeles Meléndez-Carmona, Irene Muñoz-Gallego, Mikel Mancheño-Losa, Jaime Lora-Tamayo

    Background: Antibiotic tolerance in Staphylococcus aureus biofilms poses a major clinical challenge in prosthetic joint infections (PJIs). This study aimed to characterize the antibiotic tolerance of clinical S. aureus isolates recovered from cases of PJI under different stress conditions, including biofilm formation and antibiotic exposure. The correlation between tolerance level, the presence of specific tolerance-related genes, and clinical outcome was also evaluated. Methods: Twelve clinical S. aureus isolates were analyzed. To assess tolerance, the TDtest was used on exponentially growing bacteria, 48 h biofilms, and biofilms treated with levofloxacin and/or rifampin. Whole-genome sequencing was performed to identify tolerance-associated genes. Results: All isolates were phenotypically susceptible to rifampin and levofloxacin. Although all strains exhibited basal tolerance levels, biofilm formation led to heightened antibiotic tolerance, particularly those treated with rifampin as compared to levofloxacin: 29.5 vs. 17 (p = 0.01). Rifampin tolerance in biofilm-embedded bacteria was significantly higher in isolates from patients with treatment failure (p < 0.0001). Levofloxacin tolerance showed no significant association with clinical outcomes. There was no correlation between reduction in biofilm bacterial burden after treatment and tolerance levels. Genomic analysis identified associations between higher levofloxacin tolerance and the presence of sspA and leuS in biofilm isolates, and between rifampin tolerance and prs and pgm. Conclusions: In this study, clinical S. aureus strains isolated from prosthetic joint infections exhibited considerable inter-strain variability in antibiotic tolerance, particularly under biofilm conditions. Elevated rifampin tolerance in biofilm-embedded bacteria was associated with poor clinical outcomes, underscoring the need for tolerance assessment beyond standard susceptibility testing.


  • Open Access

    Chronic lung infection by Achromobacter xylosoxidans in a patient with cystic fibrosis successfully treated with cefiderocol as a pre and post-lung transplant regimen

    by Susana Ramos Oliveira, Rodrigo Alonso-Moralejo, Virginia Pérez, Carlos Andrés Quezada, Alicia de Pablo, Irene Muñoz-Gallego, José Tiago Silva, José María Aguado, Francisco López-Medrano

    Revista Española de Quimioterapia tiene un carácter multidisciplinar y está dirigida a todos aquellos profesionales involucrados en la epidemiología, diagnóstico, clínica y tratamiento de las enfermedades infecciosas. Fundada en 1988 por la Sociedad Española de Quimioterapia.

  • Open Access

    Prolonged SARS-CoV-2 RNA detection by RT-PCR: variability in cycle threshold values over time

    by Irene Muñoz-Gallego, Amparo Rubio, Miriam Maseda, Patricia Carnicero, Lola Folgueira

    Millions of reverse transcription-polymerase chain reaction (RT-PCR) tests have been performed worldwide during the SARS-CoV-2 pandemic, using various protocols. This study evaluates the duration of SARS-CoV-2 RNA detectability by RT-PCR at body temperature and analyzes changes in cycle threshold (Ct) values over time. Positive nasopharyngeal swabs for SARS-CoV-2 RT-PCR ( n = 120) with different Ct values were collected from Hospital Universitario 12 de Octubre (Madrid, Spain, 2020). Samples were processed using an open-access protocol for the Hologic Panther Fusion system, targeting the envelope gene. They were stratified into six Ct value groups (40.0) and incubated at 37°C for 15, 30, 45, and 60 days, with RT-PCR repeated at each interval. Samples with Ct 40.0 were negative by day 15. A significant proportion of samples with Ct ≤35.0 remained positive at day 60. Positivity during incubation decreased with higher Ct values ( P < 0.001). Ct values increased over time but inconsistently by day 60. In conclusion, SARS-CoV-2 RNA can persist for months, leading to prolonged RT-PCR positivity. However, repeated RT-PCR testing introduces variability in qualitative results and Ct values, complicating clinical decisions. Patient monitoring should emphasize clinical assessment and viral viability assays rather than repeated RT-PCR testing. IMPORTANCE: This study investigates the prolonged persistence of SARS-CoV-2 detected by reverse transcription-PCR (RT-PCR) at human body temperature and the evolution of cycle threshold (Ct) values in positive respiratory samples. Our findings indicate that SARS-CoV-2 RNA can persist for months, and that repeated RT-PCR testing over time introduces variability, particularly in samples with high Ct values. This work highlights the necessity of complementing RT-PCR testing with methods assessing viral viability to avoid over-reliance on repeated testing in clinical decision-making. This study addresses a critical issue in COVID-19 diagnostics, with important implications for clinical management and infection control.


  • Open Access

    Impact of the SARS-CoV-2 Pandemic on the Epidemiology of Streptococcus pyogenes: A Five-Year Retrospective Study

    by Patricia Brañas, Fabiola Fontenla, María Victoria Castaño-Amores, Raúl Recio, Irene Muñoz-Gallego, Jennifer Villa, Esther Viedma, Lola Folgueira

    The SARS-CoV-2 pandemic significantly affected the epidemiology of Streptococcus pyogenes, a pathogen associated with various clinical presentations such as pharyngitis, scarlet fever, and invasive diseases. This study analyzed the incidence and characteristics of S. pyogenes infections between 2018 and 2023, examining 915 cases categorized as either respiratory or non-respiratory. Respiratory infections predominantly affected children, accounting for 76% of cases, with a median age of 5 [3, 8] years, while non-respiratory infections were more common in adults, with a median age of 46.5 [34, 64] years. Invasive respiratory infections, such as pneumonia and empyema, were more frequent in children (54.8%), whereas invasive non-respiratory infections, such as primarily cellulitis, were predominantly seen in adults (90.5%). A sharp decline in S. pyogenes infections was observed during the pandemic, with respiratory cases decreasing tenfold in 2020 compared to the previous year, and non-respiratory cases experiencing a twofold reduction. However, infection rates returned to pre-pandemic levels by 2022 and 2023, with a notable resurgence of invasive respiratory infections in children following a public health alert in the United Kingdom in late 2022. These findings highlight distinct infection patterns between pediatric and adult populations and emphasize the significant impact of the pandemic on respiratory infections, particularly in children.


  • Open Access

    Rapid screening of SARS-CoV-2 variants, a key tool for pandemic surveillance

    by Irene Muñoz-Gallego, María Ángeles Meléndez Carmona, Carmen Martín Higuera, Esther Viedma, Rafael Delgado, María Dolores Folgueira

    The utility of reverse transcription-polymerase chain reaction (RT-PCR) in analysis SARS-COV-2 variants was evaluated. RT-PCR tests were used to analyse the majority of new SARS-CoV-2 cases (n = 9315) in a tertiary hospital (Madrid, Spain) throughout 2021. Subsequently, whole genome sequencing (WGS) was conducted on 10.8% of these samples (n = 1002). Notably, the Delta and Omicron variants emerged rapidly. There were no discrepancies between RT-PCR and WGS results. Continuous surveillance of SARS-CoV-2 variants is essential, and RT-PCR is a highly useful method, specially during periods of high COVID-19 incidence. This feasible technique can be implemented in all SARS-CoV-2 laboratories. However, WGS remains the gold standard method for comprehensive detection of all existing SARS-CoV-2 variants.


  • Strain-to-strain variability among Staphylococcus aureus causing prosthetic joint infection drives heterogeneity in response to levofloxacin and rifampicin

    by María Ángeles Meléndez-Carmona, Mikel Mancheño-Losa, Albert Ruiz-Sorribas, Irene Muñoz-Gallego, Esther Viedma, Fernando Chaves, Françoise Van Bambeke, Jaime Lora-Tamayo

    Levofloxacin and rifampicin are the preferred treatment for prosthetic joint infection (PJI) caused by Staphylococcus aureus, especially when managed with implant retention (DAIR). However, a significant variability of success has been reported, which could be related to intrinsic characteristics of the microorganism. Our aim was to evaluate the variability in the anti-biofilm response to levofloxacin and rifampicin in a clinical collection of S. aureus. Eleven levofloxacin- and rifampicin-susceptible S. aureus isolates causing PJI managed with DAIR were included. Levofloxacin, rifampicin and levofloxacin + rifampicin were tested in an in vitro static biofilm model in microtitre plates, where 48 h biofilms were challenged with antimicrobials during 24 h. Additionally, two genetically similar strains were tested in the CDC Biofilm Reactor, where 48 h biofilms were treated during 56 h. Antimicrobial activity was assessed by viable biofilm-embedded cells recount, and by crystal violet staining. All antimicrobial regimens showed significant anti-biofilm activity, but a notable scattering in the response was observed across all strains (inter-strain coefficient of variation for levofloxacin, rifampicin and levofloxacin + rifampicin of 22.8%, 35.8% and 34.5%, respectively). This variability was tempered with the combination regimen when tested in the biofilm reactor. No correlation was observed between the minimal biofilm eradicative concentration and the antimicrobial activity. Recurrent S. aureus isolates exhibited higher biofilm-forming ability compared with strains from resolved infections (7.6 log10 cfu/cm2±0.50 versus 9.0 log10 cfu±0.07). Significant variability may be expected in response to levofloxacin and rifampicin among biofilm-embedded S. aureus. A response in the lower range, together with other factors of bad prognosis, could be responsible of treatment failure.


  • Open Access

    Microbiological and Molecular Features Associated with Persistent and Relapsing Staphylococcus aureus Prosthetic Joint Infection

    by Irene Muñoz-Gallego, María Ángeles Meléndez-Carmona, Jaime Lora-Tamayo, Carlos Garrido-Allepuz, Fernando Chaves, Virginia Sebastián, Esther Viedma

    Background: Persistent and relapsing prosthetic joint infection (PJI) due to Staphylococcus aureus presents a clinical challenge. This study aimed to provide an extensive description of phenotypic and genomic changes that could be related to persistence or relapse. Methods: Initial and second S. aureus isolates from 6 cases of persistent and relapsing PJI, along with clinical isolates from 8 cases, with favorable outcome were included. All isolates were studied by phenotypic and genotypic approaches. Results: Recurrent S. aureus isolates exhibited a significant increase in adhesive capacity, invasion and persistence compared to resolved isolates. No association was found for the presence or absence of certain genes with the persistence or relapse of PJI. All sequential isolates showed identical sequence type (ST). Resistance gene loss during the infection and a great diversity of variants in different virulence genes between the pair of strains, mainly in genes encoding adhesins such as fnbA, were observed. Conclusions: S. aureus-caused relapse and persistence PJI is associated with bacterial phenotypical and genotypical adaptation. The main paths of adaptation were persistence in the intracellular compartment, and the loss of antibiotic resistance genes and variant acquisition, especially in genes encoding adhesins.


  • Detection of BK polyomavirus genotypes to predict the development of BK polyomavirus‐associated complications in kidney transplant recipients: A retrospective analysis

    by Irene Muñoz‐Gallego, Nerea Díaz‐Madridano, Noelia Moral, Consuelo Pascual, Natalia Polanco, Esther González, Amado Andrés, María Dolores Folgueira

    Objectives: This study focused on the role that BK polyomavirus (BKPyV) genotypes can play in the development of BKPyV‐associated complications in renal transplant recipients.Methods: A retrospective observational study (January 2015 to April 2018) was conducted by analyzing BKPyV genotypes in 180 blood samples with detectable BKPyV viral load (VL) > 1000 copies/mL, from 63 renal transplant recipients. VL and BKPyV genotypes detections were based on real‐time PCR (rt‐PCR)‐specific assays.Results: Forty‐four patients (44/63 [69.8%]) were men, and the median age was 55.0 (interquartile range 49.0‐66.0 years). Eleven patients had clinical manifestations (11/63 [17.5%]). The most frequently detected genotypes were I (14/63 [22.2%]) and II (13/63 [20.6%]). Half of the patients (33/63 [52.4%]) had a mixed genotype, most with genotypes I and II (25/33 [75.8%]). Patients with infection by mixed genotypes showed VLs that were detected earlier (in the first year after transplantation) than those with a single genotype (25/33 [75.8%] vs 13/30 [43.3%], P = .009) and demonstrated greater risk of developing clinical manifestations associated with BKPyV (odds ratio 12.609, 95% confidence interval 1.503‐105.807). Moreover, patients with first BKPyV VL > 10 000 copies/mL more frequently presented mixed genotypes (12/16 [75.0%] vs 21/47 [44.7%], P = .036).Conclusions: The probability of developing clinical manifestations is higher in infections by mixed genotypes. Therefore, the detection of BKPyV genotypes by rt‐PCR can provide relevant information to stratify patients' risk of BKPyV‐associated complications and guide the clinical management of BKPyV infection in kidney transplant recipients.


  • Open Access

    Genotypic and Phenotypic Characteristics of Staphylococcus aureus Prosthetic Joint Infections: Insight on the Pathogenesis and Prognosis of a Multicenter Prospective Cohort

    by Irene Muñoz-Gallego, Esther Viedma, Jaime Esteban, Mikel Mancheño-Losa, Joaquín García-Cañete, Antonio Blanco-García, Alicia Rico, Adelaida García-Perea, Patricia Ruiz Garbajosa, Rosa Escudero-Sánchez, et al.

    Staphylococcus aureus is the leading cause of prosthetic joint infection (PJI). Beyond the antibiogram, little attention has been given to the influence of deep microbiological characteristics on patient’s prognosis. Our aim was to investigate whether microbiological genotypic and phenotypic features have a significant influence on infection pathogenesis and patient outcome. prospective multicentre study was performed, including all S. aureus PJIs (2016-2017). Clinical data, phenotypic (agr functionality, β-hemolysis, biofilm formation) and genotypic characteristics of the strains were collected. Biofilm susceptibility to antimicrobials was investigated (MBEC assay). 88 patients (39.8% men, age 74.7±14.1 years) were included. Forty-five had early post-operative (EPI), 21 chronic (CPI), and 19 hematogenous infections (HI). Twenty (22.7%) were caused by MRSA. High genotypic diversity was observed, including 16 clonal complexes (CC), CC5 being the most frequent (30.7%). agr activity was greater in EPI than CPI (55.6% vs 28.6%, p=0.041). Strains causing EPI were phenotypically and genotypically similar, regardless of symptom duration. Treatment failure (36.5%) occurred less frequently among cases treated with implant removal. In cases treated with debridement and implant retention, there were fewer failures among those who received combination therapy with rifampin. No genotypic or phenotypic characteristics predicted failure, except vancomycin MIC>=1.5 mg/L (23.1% failure vs 3.4%, p=0.044). MBEC50 was >128 mg/L for all antibiotics tested and showed no association with prognosis. S. aureus with different genotypic backgrounds is capable of causing PJI, showing slight differences in clinical presentation and pathogenesis. No major microbiological characteristics were observed to influence the outcome, including MBEC.